

Figure S1. Venn plot of common genes between three groups of DEGs.









Figure S2. Validation of GBP2. GBP2 expression differences between tumor and normal tissues in **(A)** COAD and **(D)** READ; GBP2 expression in tumor samples with different stages in **(B)** COAD and **(E)** READ; overall survival analysis of GBP2 in **(C)** COAD and **(F)** READ.
















EIF4E**PRR15****ANXA2****DDX5****TARDBP****PRSS12****HNRNPA3****PFDN2****NCF1****RGS10****C3AR1****GNG11****TYROBP****TMSB4X****C1QC**

Figure S3. Gene expression of 15 key genes associated with PHY906-CPT11 treatment between tumor and normal tissues in COAD. The red box corresponds to tumor samples and the grey box corresponds to normal samples. The vertical axis represents the relative expression of genes. * P <0.05.
















EIF4EREAD
(num(T)=92, num(N)=318)**PRR15**READ
(num(T)=92, num(N)=318)**ANXA2**READ
(num(T)=92, num(N)=318)**DDX5**READ
(num(T)=92, num(N)=318)**TARDBP**READ
(num(T)=92, num(N)=318)**PRSS12**READ
(num(T)=92, num(N)=318)**HNRNPA3**READ
(num(T)=92, num(N)=318)**PFDN2**READ
(num(T)=92, num(N)=318)**NCF1**READ
(num(T)=92, num(N)=318)**RGS10**READ
(num(T)=92, num(N)=318)**C3AR1**READ
(num(T)=92, num(N)=318)**GNG11**READ
(num(T)=92, num(N)=318)**TYROBP**READ
(num(T)=92, num(N)=318)**TMSB4X**READ
(num(T)=92, num(N)=318)**C1QC**READ
(num(T)=92, num(N)=318)

Figure S4. Gene expression of 15 key genes associated with PHY906-CPT11 treatment between tumor and normal tissues in READ. The red box corresponds to tumor samples and the grey box corresponds to non-tumor samples. The vertical axis represents the relative expression of genes. * P <0.05.




Figure S5. Expression of 15 key genes associated with PHY906-CPT11 treatment in tumor samples with different stages in COAD.
















EIF4E**PRR15****ANXA2****DDX5****TARDBP****PRSS12****HNRNPA3****PFDN2****NCF1****RGS10****C3AR1****GNG11****TYROBP****TMSB4X****C1QC**

Figure S6. Expression of 15 key genes associated with PHY906-CPT11 treatment in tumor samples with different stages in READ.
















EIF4E**PRR15****ANXA2****DDX5****TARDBP****PRSS12****HNRNPA3****PFDN2****NCF1****RGS10****C3AR1****GNG11****TYROBP****TMSB4X****C1QC**

Figure S7. Overall survival analyses of 15 key genes associated with PHY906-CPT11 treatment in COAD.




Figure S8. Overall survival analyses of 15 key genes associated with PHY906-CPT11 treatment in READ.